- ¥231bn
- ¥159bn
- ¥171bn
Brief: Nippon Shinyaku Co's sales likely rose 20 pct to nearly 100 bln yen in fiscal 2016 - Nikkei
Brief: Jazz pharmaceuticals and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan
Table: Nippon Shinyaku -9-MTH group results
Table: Nippon Shinyaku -6-MTH group results
2016 6-month group forecast
Brief: Actelion wins Swiss approval of uptravi for form of high blood pressure
Table: Nippon Shinyaku -Q1 group results
Brief: Nippon Shinyaku gets marketing approval of Uptravi in EU
Table: Nippon Shinyaku -2015/16 group results
Table: Nippon Shinyaku -9-MTH group results
Table: Nippon Shinyaku -6-MTH group results